CN105007922A - 包含maba化合物和皮质类固醇的结合物 - Google Patents

包含maba化合物和皮质类固醇的结合物 Download PDF

Info

Publication number
CN105007922A
CN105007922A CN201480010932.2A CN201480010932A CN105007922A CN 105007922 A CN105007922 A CN 105007922A CN 201480010932 A CN201480010932 A CN 201480010932A CN 105007922 A CN105007922 A CN 105007922A
Authority
CN
China
Prior art keywords
corticosteroid
amino
adrenergic agonist
treatment
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480010932.2A
Other languages
English (en)
Chinese (zh)
Inventor
莫尼卡·阿帕瑞奇维吉尔
玛尔塔·卡尔贝特默特
蒙特塞拉特·米拉尔佩克斯奎尔
阿玛迪·加瓦尔达莫尼德罗
卡洛斯·普伊格杜兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall SA filed Critical Almirall SA
Publication of CN105007922A publication Critical patent/CN105007922A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480010932.2A 2013-02-27 2014-02-27 包含maba化合物和皮质类固醇的结合物 Pending CN105007922A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13382060.5 2013-02-27
EP13382060 2013-02-27
US201361804558P 2013-03-22 2013-03-22
US61/804,558 2013-03-22
EP13382290 2013-07-16
EP13382290.8 2013-07-16
PCT/EP2014/053874 WO2014131852A1 (en) 2013-02-27 2014-02-27 Combinations comprising maba compounds and corticosteroids

Publications (1)

Publication Number Publication Date
CN105007922A true CN105007922A (zh) 2015-10-28

Family

ID=51427547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480010932.2A Pending CN105007922A (zh) 2013-02-27 2014-02-27 包含maba化合物和皮质类固醇的结合物

Country Status (11)

Country Link
US (1) US20160015704A1 (enExample)
EP (1) EP2988745A1 (enExample)
JP (1) JP2016510012A (enExample)
KR (1) KR20150120391A (enExample)
CN (1) CN105007922A (enExample)
AU (1) AU2014222646A1 (enExample)
BR (1) BR112015019587A2 (enExample)
CA (1) CA2901869A1 (enExample)
TW (1) TW201440768A (enExample)
UY (1) UY35354A (enExample)
WO (1) WO2014131852A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512528A (zh) * 2018-07-30 2021-03-16 维克公司 糖皮质激素在治疗哺乳动物中具有天然外口的含流体器官的上皮微生物感染的新用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EA201500651A1 (ru) 2012-12-18 2015-11-30 Альмираль, С.А. НОВЫЕ ПРОИЗВОДНЫЕ ЦИКЛОГЕКСИЛ- И ХИНУКЛИДИНИЛКАРБАМАТА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
WO2018011090A1 (en) * 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA3109658A1 (en) * 2018-08-13 2020-02-20 The Regents Of The University Of Michigan Use of jak inhibitors in the treatment of amyotrophic lateral sclerosis (asl)
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096127A2 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators
WO2011141180A1 (en) * 2010-05-13 2011-11-17 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524897A (ja) * 2008-06-20 2011-09-08 アストラゼネカ・アクチエボラーグ β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物
DE102010016629B4 (de) * 2010-04-23 2015-11-19 FLUORON GmbH Gesellschaft für hochreine Biomaterialien Vorrichtung mit Vitrektomielinse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096127A2 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators
WO2011141180A1 (en) * 2010-05-13 2011-11-17 Almirall, S.A. NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周新: "哮喘治疗新药临床应用及开发进展", 《世界临床药物》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512528A (zh) * 2018-07-30 2021-03-16 维克公司 糖皮质激素在治疗哺乳动物中具有天然外口的含流体器官的上皮微生物感染的新用途
US11819506B2 (en) 2018-07-30 2023-11-21 Virbac Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals
US12478629B2 (en) 2018-07-30 2025-11-25 Virbac Use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals

Also Published As

Publication number Publication date
EP2988745A1 (en) 2016-03-02
BR112015019587A2 (pt) 2017-07-18
TW201440768A (zh) 2014-11-01
CA2901869A1 (en) 2014-09-04
WO2014131852A1 (en) 2014-09-04
KR20150120391A (ko) 2015-10-27
UY35354A (es) 2014-09-30
US20160015704A1 (en) 2016-01-21
AU2014222646A1 (en) 2015-08-13
JP2016510012A (ja) 2016-04-04

Similar Documents

Publication Publication Date Title
CN105007922A (zh) 包含maba化合物和皮质类固醇的结合物
CN105407890B (zh) 包含maba化合物和皮质类固醇的结合物
JP5133054B2 (ja) 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤
TWI419691B (zh) 藥劑組成物（一）
TWI439296B (zh) 藥劑組成物（二）
MXPA06013849A (es) Combinaciones que comprenden agentes antimuscarinicos e inhibidores de pde4.
CN103288729A (zh) 5-(2-{[6-(2,2-二氟-2-苯基乙氧基)己基]胺基}-1-羟乙基)-8-羟基喹啉-2(1h)-酮及其在治疗肺病中的用途
CN102325530A (zh) 用于治疗肺功能的5-(2-{[6-(2,2-二氟-2-苯基乙氧基)己基]胺基}-1-羟乙基)-8-羟基喹啉-2(1h)-酮

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151028

RJ01 Rejection of invention patent application after publication